Form 4 for NRXP NRX Pharmaceuticals, Inc.
Accepted 2022-12-09 00:00:00 ET · period of report 2022-12-07 · accession 0001415889-22-012324 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-12-09 | 2022-12-07 | NRXP | Javitt Jonathan C | Dir, 10% | S - Sale | $1.00 | -400.0K | 12.90M | -3% | -$400.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.001 per share | 2022-12-07 | S | D | 400,000 | $1.00 | 12,899,997 | I By Trust | — | — | (F1) Private sale pursuant to an option granted by the Reporting Person in 2017 in support of a financing for NeuroRx, Inc. Purchaser has agreed to hold the shares for a period of one year. (F2) Held by the Jonathan Javitt Living Trust. The Reporting Person is a trustee of the Trust. |